Fig. 3. Association between the Blue_response signature score and the rate of pathological complete response (pCR) in non-TMO-based breast cancer cohorts treated with neoadjuvant chemotherapy.  The remaining 46 cohorts were generated on non-TMO platforms, and direct comparison of signature scores across cohorts is currently not feasible.  Therefore, samples within each cohort were instead stratified using tertile splits of the signature score (i.e. high: > 2/3 percentile; low ≤ 1/3 percentile; medium: ≤ 2/3 percentile and >1/3 percentile).